Professionals Services Insights Community About Offices Careers
Home / Professionals / Daniel J. Minion
PDF

Daniel J. Minion

Partner
Minion Daniel
vCard
dminion@Venable.com
New York - Rockefeller Center
T +1 212.218.2538 F +1 212.218.2200
Dan Minion is a patent litigator who focuses on Hatch-Waxman litigation, chemicals litigation, and contested proceedings before the U.S. Patent and Trademark Office.  In addition to first-chair litigation before District Courts, he has argued on behalf of major pharmaceutical companies at the U.S. Court of Appeals for the Federal Circuit and the Patent Trial and Appeal Board (for both petitioner and patent owner).  Dan has counseled on a wide range of pharmaceuticals in a variety of formulations used to treat breast and prostate cancer, renal disease, hypertension, arrhythmias, chronic pain, epilepsy, hormonal and genetic disorders, osteoporosis, Alzheimer’s, and multiple sclerosis.

Before joining Venable, Dan spent his entire career in private practice at Fitzpatrick, Cella, Harper & Scinto. 

Prior to law school, Dan worked as a medicinal chemist at Agouron Pharmaceuticals and obtained a master’s degree in organic chemistry for his synthetic studies on the viridin family of kinase inhibitors. 

 

Related Practices

Experience

Representative Matters

  • Represented Sanofi Genzyme against several generics on patents relating to Cerdelga® for the treatment of Gaucher disease (D. Del.)
  • Represented Grünenthal against Antecip in contested proceedings in the USPTO relating to the use of bisphosphonates for the treatment of chronic pain (PTAB)
  • Represented Sanofi against several generics on patents relating to Jevtana® for the treatment of prostate cancer (D.N.J., PTAB, Fed. Cir.)
  • Represented Sanofi against several generics on patents relating to Multaq® for the treatment of atrial fibrillation (D. Del., Fed. Cir.)
  • Represented Novartis against several generics on patents relating to Exelon Patch® for the treatment of Alzheimer’s disease (D. Del.)
  • Represented Bone Care and Genzyme against several generics on patents relating to Hectorol® for the treatment of kidney disease (ND Ill., D. Del.)
  • Represented Novartis against Mylan on a patent relating to Femara® for the treatment of breast cancer (D. N.J.)
 

Representative Clients

  • Sanofi/Genzyme
  • Novartis

Insights

Thought Leadership

1/12/2017

Federal Circuit Affirms Finding That Teva And Other Drug Makers Would Induce Infringement Of Eli Lilly Method Patent Where Drug Makers’ Product Labels Instruct Doctors To Perform Certain Steps Of Patented Method And Patients To Perform Remaining Steps
Federal Circuit Affirms Finding That Teva And Other Drug Makers Would Induce Infringement Of Eli Lilly Method Patent Where Drug Makers’ Product Labels Instruct Doctors To Perform Certain Steps Of Patented Method And Patients To Perform Remaining Steps

Events

April 29 - 30, 2019 New York, NY

ACI’s 13th Annual PIV Disputes Conference
ACI’s 13th Annual PIV Disputes Conference

Recent News

August 28, 2019

Venable Fitzpatrick Wins at Federal Circuit on Behalf of Sanofi
Venable Fitzpatrick Wins at Federal Circuit on Behalf of Sanofi

May 08, 2019

Venable Fitzpatrick Successfully Defends Patent Related to Sanofi’s JEVTANA® Product
Venable Fitzpatrick Successfully Defends Patent Related to Sanofi’s JEVTANA® Product

May 03, 2019

Law360 Covers Venable's Win in Post-Grant Review Before Patent Trial and Appeal Board
Law360 Covers Venable's Win in Post-Grant Review Before Patent Trial and Appeal Board

Credentials
+

Education

  • J.D. Benjamin N. Cardozo School of Law 2006
  • M.S. Organic Chemistry University of Pittsburgh 2004
  • B.S. Chemistry Stanford University 1996

Bar Admissions

  • New York
  • United States Patent and Trademark Office

Court Admissions

  • U.S. District Court for the Southern District of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. Court of Appeals for the Federal Circuit

Recognition
+

  • Named a Rising Star in Intellectual Property Litigation, Super Lawyers: New York Metro Edition, 2015-2017